Cortexyme, Inc.

106 articles with Cortexyme, Inc.

• Cortexyme Announces First Quarter 2020 Financial Results and Provides Business Update

  5/12/2020

  Cortexyme, Inc., a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, announced financial results for the first quarter 2020 and provided an update on its business.

• Cortexyme to Present at the BofA Securities 2020 Health Care Conference on May 13, 2020

  5/7/2020

  Cortexyme to Present at the BofA Securities 2020 Health Care Conference on May 13, 2020 -- Presentation to be webcast on Cortexyme’s website SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch

• Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons, Drive Alzheimer’s-Like Pathology in the Journal of Alzheimer’s Disease

  5/6/2020

  May 6, 2020 12:30 UTC Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons, Drive Alzheimer’s-Like Pathology in the Journal of Alzheimer’s Disease   SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s (AD) and other degenerative diseases, today announced the pu

• Cortexyme Appoints Caryn McDowell, J.D. as Chief Legal and Administrative Officer and Corporate Secretary

  4/30/2020

  Cortexyme, Inc. (Nasdaq: CRTX), a biopharmaceutical company developing treatments for Alzheimer’s disease (AD) and other degenerative diseases, today announced Caryn McDowell, J.D. will join the company’s executive leadership team as Chief Legal and Administrative Officer and Corporate Secretary, effective May 11, 2020.

• Cortexyme to Present at the LifeSci Capital Alpha Series Virtual Conference on April 9, 2020

  4/6/2020

  Presentation to be webcast on Cortexyme’s website --

• Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimer’s Pathology at Advances in Alzheimer’s and Parkinson’s Therapies Virtual Focus Meeting 2020

  4/2/2020

  -- New results demonstrate P. gingivalis’ ability to infect neurons and cause characteristic Alzheimer’s pathology

• Cortexyme Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

  3/17/2020

  Following initial public offering and private placement, Cortexyme is well capitalized and focused on high quality execution of the Phase 2/3 GAIN Trial

• Cortexyme Announces Gain Trial in Alzheimer’s Disease Has Reached Enrollment Milestone of 300 Patients

  3/16/2020

  Cortexyme, Inc. (Nasdaq: CRTX) today announced that enrollment in its GAIN Trial for Alzheimer’s disease has reached 300 patients toward the study's previously announced enrollment

• Cortexyme Provides Regulatory Update for COR388 Development Program in Alzheimer’s Disease

  2/13/2020

  Cortexyme, Inc.. (Nasdaq: CRTX) today provided an update on its clinical development plans for COR388, the company’s lead investigational medicine in development for mild to moderate Alzheimer’s disease (AD).

• Cortexyme Announces Closing of $125 Million Private Placement

  2/10/2020

  Cortexyme, Inc., a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, announced that it has closed its private placement offering.

• Cortexyme Announces $125 Million Private Placement

  2/6/2020

  Cortexyme, Inc. announced that it has entered into stock purchase agreements with a group of institutional investors and an entity affiliated with a member of the Company’s Board of Directors in connection with a private placement of its common stock.

• Cortexyme Announces Publication of New Data Further Demonstrating the Therapeutic Potential of COR388, the Company’s Lead Investigational Medicine

  1/30/2020

  Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced the publication of new data in Pharmacology Research and Perspectives revealing further detail about the pharmacodynamics and utility of the company’s lead investigational medicine, COR388.

•  Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimer’s Disease

  1/13/2020

  Cortexyme, Inc. announced it is initiating an open-label extension study in the United States for its Phase 2/3 GAIN Trial of COR388 in subjects with mild to moderate Alzheimer’s disease.

• Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020

  1/8/2020

  Corporate presentation by CEO Casey Lynch will be webcast live Lynch will also participate in a roundtable session earlier in the day

• Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimer’s Disease

  12/7/2019

  In a Phase 1b trial, COR388 reduced levels of fragmented ApoE protein in cerebrospinal fluid of subjects with Alzheimer’s

• Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update

  11/12/2019

  Lead investigational medicine COR388, a potentially transformative new paradigm for addressing Alzheimer’s disease, continues to advance in Phase 2/3 GAIN clinical trial

• Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimer’s Disease 2019

  11/1/2019

  Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced that its lead investigational medicine, COR388, will be the subject of an oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2019.

• Cortexyme Announces European Screening Now Underway in the Phase 2/3 GAIN Trial

  9/26/2019

  Cortexyme, Inc. announced the start of screening in Europe for the GAIN Trial, the company’s ongoing Phase 2/3 clinical study of lead investigational medicine COR388 in subjects with mild to moderate Alzheimer’s disease.

• 

  Alzheimer’s Disease Insight Report: Current Therapies, Drug Pipeline and Outlook

  9/23/2019

  50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.

• Cortexyme to Present at the Canaccord Genuity Growth Conference on August 7th

  7/31/2019

  Cortexyme, Inc. announced Casey Lynch, the company’s chief executive officer, chairman, and co-founder, will present at the Canaccord Genuity Growth Conference on Wednesday, August 7th, 2019 at 9:00 a.m. EDT (6:00 a.m. PDT) in Boston.